Market cap
₹1 Cr
Revenue (TTM)
₹-- Cr
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 0.00 | 3.03 | 12.99 | 0.72 | 7.41 |
| Net Profit | 0.00 | 3.03 | 13.16 | 0.50 | 9.91 |
| EPS | 0.00 | 2.99 | 13.11 | 21.97 | 9.90 |
| Book Value | -- | -- | -0.89 | -25.88 | 1.23 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-12 | Mar-11 |
| EBIT-Margin
| -1,168.52 | -579.40 | -- | -- | -1,432.51 |
| Net Margin
| -1,115.26 | -558.01 | -- | -- | -1,304.14 |
| Return on equity
| -28.95 | -13.63 | -- | -1.24 | -4.11 |
| Return on Capital
| -16.81 | -6.97 | -- | -0.56 | -1.90 |
| Return on Assets
| -12.94 | -7.01 | -0.60 | -0.40 | -1.32 |
| Debt to Equity (x)
| -- | -- | 0.68 | 1.18 | 1.16 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-0.56
|
-1.89
|
-47.98
|
0.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-1.24
|
-4.03
|
-81.59
|
-4.41
|
|
Peer Median
|
3.56
|
--
|
--
|
--
|
--
|
ROA
-0.60
Lower than Peers by 1.58
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
-0.60
|
-0.40
|
-1.32
|
-37.09
|
-1.93
|
|
Peer Median
|
0.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
-1,432.51
|
-904.53
|
1.89
|
|
Peer Median
|
7.69
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-2,757.31
|
-1,304.14
|
-926.38
|
-11.83
|
|
Peer Median
|
4.52
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
-1,258.51
|
-671.94
|
-7.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-100.00
|
-98.11
|
-72.70
|
-51.67
|
|
Peer Median
|
4.01
|
--
|
--
|
--
|
--
|
EBIT Growth
12.99
Higher than Peers by 15.33
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
12.99
|
69.40
|
97.01
|
-13,162.83
|
-94.80
|
|
Peer Median
|
-2.34
|
--
|
--
|
--
|
--
|
Net Profit Growth
13.16
Higher than Peers by 13.71
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
13.16
|
70.07
|
97.10
|
-2,036.64
|
-155.05
|
|
Peer Median
|
-0.55
|
--
|
--
|
--
|
--
|
EPS Growth
13.11
--
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
13.11
|
70.06
|
97.10
|
-2,036.64
|
-127.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-0.89
|
-3.63
|
-57.37
|
323.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.68
Higher than Peers by 0.54
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.68
|
1.18
|
1.16
|
1.10
|
0.47
|
|
Peer Median
|
0.14
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.24
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.24
|
0.23
|
0.23
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.57
Lower than Peers by 0.85
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.57
|
0.63
|
0.63
|
0.91
|
5.45
|
|
Peer Median
|
1.42
|
--
|
--
|
--
|
--
|
Quick Ratio
0.57
Lower than Peers by 0.57
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.57
|
0.63
|
0.63
|
0.91
|
5.11
|
|
Peer Median
|
1.15
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
-114.15
|
-818.17
|
-38.58
|
0.15
|
|
Peer Median
|
1.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
752.28
|
12.28
|
87.87
|
|
Peer Median
|
26.87
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
0.00
|
0.05
|
0.20
|
|
Peer Median
|
0.30
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
2,559.66
|
444.28
|
263.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
--
|
183.27
|
106.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
--
|
925.24
|
799.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
2,559.66
|
-297.69
|
-429.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
419.92
|
--
|
--
|
--
|
--
|
Price / Book Value
0.05
Lower than Peers by 2.19
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
0.05
|
0.28
|
0.50
|
1.07
|
0.28
|
|
Peer Median
|
2.24
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-677.96
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
-677.96
|
-191.02
|
-45.59
|
-1.64
|
-9.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1
Lower than Peers by 253
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Mar-09
|
|---|---|---|---|---|---|
|
ABL Biotechnologies
|
1
|
--
|
7
|
16
|
10
|
|
Peer Median
|
253
|
--
|
--
|
--
|
--
|